Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs

References

• Cerezo-WallisDSoengasMUnderstanding tumor-antigen presentation in the new era of cancer immunotherapyCurr Pharm Des201622416234625027568731
   PubMedGoogle Scholar
• MarkowitzJWesolowskiRPapenfussTBrooksTRCarsonWE3rdMyeloid-derived suppressor cells in breast cancerBreast Cancer Res Treat20131401132123828498
   PubMed Web of Science ®Google Scholar
• TagliamonteMPetrizzoATorneselloMLBuonaguroFMBuonaguroLAntigen-specific vaccines for cancer treatmentHum Vaccin Immunother201410113332334625483639
   PubMed Web of Science ®Google Scholar
• NefedovaYFishmanMShermanSWangXBegAAGabrilovichDIMechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cellsCancer Res20076722110211102818006848
   PubMed Web of Science ®Google Scholar
• YounJINagarajSCollazoMGabrilovichDISubsets of myeloid-derived suppressor cells in tumor-bearing miceJ Immunol200818185791580218832739
   PubMed Web of Science ®Google Scholar
• AlcorloMMartinez-BarricarteRFernandezFJUnique structure of iC3b resolved at a resolution of 24 A by 3D-electron microscopyProc Natl Acad Sci U S A201110832132361324021788512
   PubMedGoogle Scholar
• KullbergMMartinsonHMannKAnchordoquyTJComplement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cellsNanomedicine20151161355136325839391
   PubMedGoogle Scholar
• FanYMoonJJNanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapyVaccines (Basel)20153366268526350600
   PubMed Web of Science ®Google Scholar
• JoshiMDUngerWJStormGvan KooykYMastrobattistaETargeting tumor antigens to dendritic cells using particulate carriersJ Control Release20121611253722580109
   PubMed Web of Science ®Google Scholar
• IracheJMSalmanHHGamazoCEspuelasSMannose-targeted systems for the delivery of therapeuticsExpert Opin Drug Deliv20085670372418532925
   PubMed Web of Science ®Google Scholar
• XuLAnchordoquyTDrug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeuticsJ Pharm Sci20111001385220575003
   PubMed Web of Science ®Google Scholar
• MerleNSChurchSEFremeaux-BacchiVRoumeninaLTComplement system part I – molecular mechanisms of activation and regulationFront Immunol2015626226082779
   PubMed Web of Science ®Google Scholar
• MerleNSNoeRHalbwachs-MecarelliLFremeaux-BacchiVRoumeninaLTComplement system part II: role in immunityFront Immunol2015625726074922
   PubMed Web of Science ®Google Scholar
• KullbergMMannKAnchordoquyTJTargeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLOMol Pharm2012972000200822621404
   PubMedGoogle Scholar
• LawSKDoddsAWThe internal thioester and the covalent binding properties of the complement proteins C3 and C4Protein Sci1997622632749041627
   PubMed Web of Science ®Google Scholar
• HourcadeDEThe role of properdin in the assembly of the alternative pathway C3 convertases of complementJ Biol Chem200628142128213216301317
   PubMedGoogle Scholar
• TurnerNSartainSMoakeJUltralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromesHematol Oncol Clin North Am201529350952426043389
   PubMed Web of Science ®Google Scholar
• HessMWSchwendingerMGEskelinenELTracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21)Blood20009582617262310753842
   PubMedGoogle Scholar
• GeyerMBBrentjensRJReview: current clinical applications of chimeric antigen receptor (CAR) modified T cellsCytotherapy201618111393140927592405
   PubMed Web of Science ®Google Scholar
• SolimanHImmunotherapy strategies in the treatment of breast cancerCancer Control2013201172123302903
   PubMed Web of Science ®Google Scholar
• AlmandBResserJRLindmanBClinical significance of defective dendritic cell differentiation in cancerClin Cancer Res2000651755176610815894
   PubMed Web of Science ®Google Scholar
• Diaz-MonteroCMSalemMLNishimuraMIGarrett-MayerEColeDJMonteroAJIncreased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapyCancer Immunol Immunother2009581495918446337
   PubMed Web of Science ®Google Scholar
• KusmartsevSChengFDYuBAll-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccinationCancer Research200363154441444912907617
   PubMed Web of Science ®Google Scholar
• MirzaNFishmanMFrickeIAll-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patientsCancer Res200666189299930716982775
   PubMed Web of Science ®Google Scholar
• UgelSDelpozzoFDesantisGTherapeutic targeting of myeloid-derived suppressor cellsCurr Opin Pharmacol20099447048119616475
   PubMed Web of Science ®Google Scholar
• CandolfiMCurtinJFYagizKB cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastomaNeoplasia2011131094796022028620
   PubMed Web of Science ®Google Scholar
• SchultzeJLMichalakSSeamonMJCD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapyJ Clin Invest199710011275727659389740
   PubMedGoogle Scholar
• ThomasSPrendergastGCCancer vaccines: a brief overviewMethods Mol Biol2016140375576127076165
   PubMedGoogle Scholar
• BuschDHFrassleSPSommermeyerDBuchholzVRRiddellSRRole of memory T cell subsets for adoptive immunotherapySemin Immunol2016281283426976826
   PubMedGoogle Scholar
• XuYDottiGSelection bias: maintaining less-differentiated T cells for adoptive immunotherapyJ Clin Invest20161261353726657855
   PubMed Web of Science ®Google Scholar
• BarringtonRASchneiderTJPitcherLAUncoupling CD21 and CD19 of the B-cell coreceptorProc Natl Acad Sci U S A200910634144901449519706534
   PubMedGoogle Scholar
• LyubchenkoTDal PortoJMHolersVMCambierJCCutting edge: complement (C3d)-linked antigens break B cell anergyJ Immunol200717952695269917709481
   PubMedGoogle Scholar
• NielsenCHMarquartHVProdingerWMLeslieRGCR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytesImmunology2001104441842211899427
   PubMedGoogle Scholar
• NiyonzimaNHalvorsenBSporsheimBComplement activation by cholesterol crystals triggers a subsequent cytokine responseMol Immunol201784435027692470
   PubMedGoogle Scholar
• LindauDGielenPKroesenMWesselingPAdemaGJThe immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cellsImmunology2013138210511523216602
   PubMed Web of Science ®Google Scholar